Gilead prices COVID-19 drug candidate remdesivir at $2,340 per patient - Reuters UK
6:26am PDT - June 29th, 2020 remdesivir - ReutersGilead Sciences Inc has priced its COVID-19 drug candidate remdesivir at $2,340 (1,901 pounds) for a five-day treatment in the United States and some other developed countries, it said on Monday, as it set the price for a single vial at $390.